Drive-Through Screening Center for COVID-19: a Safe and Efficient Screening System against Massive Community Outbreak

As the coronavirus disease 2019 (COVID-19) outbreak is ongoing, the number of individuals to be tested for COVID-19 is rapidly increasing. For safe and efficient screening for COVID-19, drive-through (DT) screening centers have been designed and implemented in Korea. Herein, we present the overall concept, advantages, and limitations of the COVID-19 DT screening centers. The steps of the DT centers include registration, examination, specimen collection, and instructions. The entire service takes about 10 minutes for one testee without leaving his or her cars. Increased testing capacity over 100 tests per day and prevention of cross-infection between testees in the waiting space are the major advantages, while protection of staff from the outdoor atmosphere is challenging. It could be implemented in other countries to cope with the global COVID-19 outbreak and transformed according to their own situations.

[1]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[2]  A. Cassone,et al.  Effects of chloroquine on viral infections: an old drug against today's diseases , 2003, The Lancet Infectious Diseases.

[3]  M. Petri,et al.  Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines , 2018, Arthritis Research & Therapy.

[4]  Jianjun Gao,et al.  Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. , 2020, Bioscience trends.

[5]  J. Chu,et al.  An evaluation of Chloroquine as a broad-acting antiviral against Hand, Foot and Mouth Disease. , 2018, Antiviral research.

[6]  K. Rainsford,et al.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases , 2015, Inflammopharmacology.

[7]  Report on the Epidemiological Features of Coronavirus Disease 2019 (COVID-19) Outbreak in the Republic of Korea from January 19 to March 2, 2020 , 2020, Journal of Korean medical science.

[8]  L. Sehulster,et al.  Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). , 2003, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[9]  D. Plantone,et al.  Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review , 2018, Clinical Drug Investigation.

[10]  Philippe Colson,et al.  Chloroquine for the 2019 novel coronavirus SARS-CoV-2 , 2020, International Journal of Antimicrobial Agents.

[11]  Jae-Won Park,et al.  Pharmacokinetics of Hydroxychloroquine and Its Clinical Implications in Chemoprophylaxis against Malaria Caused by Plasmodium vivax , 2009, Antimicrobial Agents and Chemotherapy.

[12]  Gregory H. Gilbert,et al.  Drive-through medicine: a novel proposal for rapid evaluation of patients during an influenza pandemic. , 2010, Annals of emergency medicine.

[13]  David Willauer,et al.  Mass prophylaxis dispensing concerns: traffic and public access to PODs. , 2011, Biosecurity and bioterrorism : biodefense strategy, practice, and science.

[14]  Lewis J Radonovich,et al.  Respirator tolerance in health care workers. , 2009, JAMA.

[15]  Sumiko Mekaru,et al.  Open access epidemiological data from the COVID-19 outbreak , 2020, The Lancet Infectious Diseases.